OBJECTIVE: The objective of this selective EBM review is to determine whether or not the use of curcumin, versus a placebo, is effective in changing cognitive function. STUDY DESIGN: Review of 3 randomized control trials with blinding in English from 2008 to present. DATA SOURCES: Articles were selected from Cochrane and PubMed databases based on relevance to the selected research question and patient-centered outcomes. OUTCOME(S) MEASURED: The outcome measured is cognitive change, evaluated by mean score changes in the Mini Mental Status Examination (MMSE) or the Montreal Cognitive Assessment (MoCA). RESULTS: Two of the studies demonstrated no change in cognitive function measured with the MMSE (Ringman JM, Frautschy SA, Teng E, et al. Alzheimers Res Ther. 2012;4(5):43. doi: 10.1186/alzrt146. and Baum, L, Lam CW, Cheung SK, et al. J Clin Psychopharmocol. 2008;28(1):110-113. doi: 10.1097/jcp0b013e318160862c), while the third article also did not demonstrate a change in cognitive function, as measured by the MoCA (Rainey-Smith SR, Brown BM, Sohrabi HR, et al. Br J Nutr. 2016;115(12):2106-2113. doi: 10.1017/S0007114516001203). CONCLUSIONS: The studies are unable to demonstrate that curcumin is more effective than placebo in preventing cognitive changes.